Clinical research
Houston, TX - BreviTest Technologies has been awarded a $1,500,000 grant from the National Institute on Drug Abuse of the National Institutes of Health to further the commercialization of its point-of-care analyzer for rapid opioid urine testing.
Calls for increased transparency in clinical trials have been growing and now many medical journals are requiring authors of submitted papers to disclose whether or not they will be sharing clinical trial results.
The drug showed what the company is calling a “substantial improvement in this symptom-driven score” at the 12-week point, but it did not differentiate from placebo.
MacroGenics’ metastatic HER2-positive breast cancer treatment margetuximab continues to show promise following a second pre-planned interim overall survival analysis of its Phase III SOPHIA trial.
The pharmaceutical company Biogen announced they plan to file for US marketing approval of the potential Alzheimer’s drug, aducanumab.
Porton Biopharma Ltd has announced that it has signed a modification to its contract with the US National Institute of Health’s National Institute of Allergy and Infectious Diseases to advance a next generation intra-nasal anthrax vaccine into the clinical-trial phase.
Tucatinib is an oral tyrosine kinase inhibitor that is highly selective for HER2 without significantly inhibiting EGFR.
The trial met its co-primary endpoints, showing statistically significant and clinically meaningful improvements in overall survival and progression-free survival compared to standard-of-care, Bayer’s Nexavar.
Last week was busy for clinical trial news. Here’s a look.
Janssen Pharmaceutical of Johnson & Johnson released new long-term data from the open-label period of its Phase III VOYAGE 1 clinical trial.
PRESS RELEASES